Zulu Nomusa 🗸 💈



KZN Health Intranet

Search this site

KZN HEALTH

CORPORATE INFORMATION


COMPONENTS DIRECTORY

DISTRICT OFFICES HEALTH FACIL

KZN Health > Components > Supply Chain Management

AdvertQuote

KWAZULU-NATAL PROVIN HEALTH REPUBLIC OF SOUTH AFRICA	<u>ice</u> Quotation Advert				
Opening Date:	2022-11-18				
Closing Date:	2022-11-25				
Closing Time:	11:00				
INSTITUTION DETAILS					
Institution Name:	Catherine Booth hospital				
Province:	KwaZulu-Natal				
Department or Entity:	Department of Health				
Division or section:	Central Supply Chain Management				
Place where goods / services is required	CATHERINE BOOTH HOSPITAL				
Date Submitted	2022-11-17				
ITEM CATEGORY AND DETAILS					
Quotation Number:	ZNQ: CBH00115/22-23				
Item Category:	Goods				
Item Description:	SUPPLY AND DELIVER PHARMACY INTERGRATED TB-HIV PRESCRIPTION BOOKLET.				
Quantity (if supplies)	300				
COMPULSORY BRIEFING SESSION	/ SITE VISIT				
Select Type:	Select 💙				
Date:	EE				
Time:					
Venue:					
QUOTES CAN BE COLLECTED FROM:	DEPT OF ADVERTISING WEB-SITE				
QUOTES SHOULD BE DELIVERED TO:	CBH TENDER-BOX/ EMAIL nompelelo.zulu@kznhealth.gov.za				
ENQUIRIES REGARDING THE ADVE	RT MAY BE DIRECTED TO:				
Name:	SONJA ENOCK				
Email:	sonja.enock@kznhealth.gov.za				
Contact Number:	035 474 8407 ext 1276				
Finance Manager Name:	MR O. N. DLUDLA				
Finance Manager Signature	00 184				



STANDARD QUOTE DOCUMENTATION OVER R30 000.00 YOU ARE HEREBY INVITED TO QUOTE FOR REQUIREMENTS AT: CATHERINE BOOTH HOSPITAL: DATE ADVERTISED. 18/11/2022 CLOSING DATE: 25/11/2022 E-MAIL ADDRESS: nompelelo.zulu@kznhealth.gov.za FACSIMILE NUMBER: 086 248 0976 PHYSICAL ADDRESS: KWA- KHOZA RESERVE, AMATIKULU 3801 QUOTE NUMBER: SUPPLY AND DELIVER PHARMACY INTERGRATED TB-HIV PRESCRIPTION BOOKLET X300 SARS PIN. CONTRACT PERIOD ONCE -OFF VALIDITY PERIOD 60 Days (if applicable) М Α Α CENTRAL SUPPLIER DATABASE REGISTRATION (CSD) NO. UNIQUE REGISTRATION REFERENCE DEPOSITED IN THE QUOTE BOX SITUATED AT (STREET ADDRESS) CATHERINE BOOTH HOSPITAL NEAR ADMIN OFFICES OR EMAIL TO nompelelo.zulu@kznhealth.gov.za (FAX NR 0862480976) Bidders should ensure that quotes are delivered timeously to the correct address. If the quote is late, it will not be accepted for consideration. The quote box is open from 08:00 to 15:30. QUOTATIONS MUST BE SUBMITTED ON THE OFFICIAL FORMS - (NOT TO BE RETYPED) THIS QUOTE IS SUBJECT TO THE PREFERENTIAL PROCUREMENT POLICY FRAMEWORK ACT AND THE PREFERENTIAL PROCUREMENT REGULATIONS, 2011, THE GENERAL CONDITIONS OF CONTRACT (GCC) AND, IF APPLICABLE, ANY OTHER SPECIAL CONDITIONS OF CONTRACT. THE FOLLOWING PARTICULARS MUST BE FURNISHED (FAILURE TO DO SO MAY RESULT IN YOUR QUOTE BEING DISQUALIFIED) NAME OF BIDDER POSTAL ADDRESS STREET ADDRESS TELEPHONE NUMBER CODE......NUMBER...... FACSIMILE NUMBER CODENUMBER...... CELLPHONE NUMBER E-MAIL ADDRESS VAT REGISTRATION NUMBER (If VAT vendor) YES NO HAS A B-BBEE STATUS LEVEL VERIFICATION CERTIFICATE BEEN SUBMITTED? (SBD 6.1)

[A B-BBEE STATUS LEVEL VERIFICATION CERTIFICATE/SWORN AFFIDAVIT (FOR EMES& QSES) MUST BE SUBMITTED TO QUALIFY

FOR PREFERENCE POINTS FOR B-BBEE]

		FOR QUOTATIONS OVER R30 000	FED TR. HIV P	QUOTE NUMBER: CBH0115/22-23 IV PRESCRIPTION BOOKLET							
DESCRIPT	ION:	Y AND DELIVEH PHAHMACY INTERGRA	IED IB-DIA E	neochie i con	BOOKE	erika di kacamatan di kacamatan Kacamatan di kacamatan di kacama	******				
SIGNATUR [By signing	E OF BIDDE this documer	R		DATE							
CAPACITY	UNDER WH	ICH THIS QUOTE IS SIGNED	***************************************								
Item No	Quantity	Description		Brand &	Country of	Price	·				
				model	manufacture	R	C				
	ļ	SUPPLY AND DELIVER		,							
1.	300	PHARMACY INTERGRATED TB-HIV PRES	SCRIPTION				-				
		BOOKLET FOR MDR-TBCP SERVICES			· · · · · · · · · · · · · · · · · · ·						
							+				
							-				
					<u></u>						
		SEE ATTACHED BOOKLET									

	1										
							-				
		POCUMENTO PEOLIDED.									
		DOCUMENTS REQUIRED:	······								
·····		VALID TAX CLEARANCE CERTIFICA									
		ABOVE FULL CSD SUMMARY REPOR	RT								
		N.B. FAILURE TO COMPLY WITH THE A					+				
-		RESULT IN YOUR IN YOUR BID BEING P	ASSED								
		OVER AWARDED SUPPLIER TO DELIVE	R								
		2 WEEKS AFTER RECEIVING AN ORDER									
		15% (Only if VAT Vendor)									
TOTAL QU	JOTATION P	RICE (VALIDITY PERIOD 60 Days)									
<u> </u>											
			The Article		The S.A.N.S. / S	S.A.B.S.					
			Specification?		nk						
Is The Pric	e Firm?		elivery Period,	, ө.д., <i>1day, 1we</i> с	7X						
Contact Pe	erson: MS S	ne <u>quote</u> may be directed to: . ENOCKTel:_035 474 8403 enock@kznhealth.gov.za			nical information may						



Prescription for Integration of Drug Resistant Tuberculosis, HIV

And Non-Communicable Diseases Management

2		I	3
START / STOP CHANGE DATE	DR TB REGIMEN	Hospital Practice Number	Initiating Hospital
GE D,	IME	ita	T
ATE ATE	Z	<u></u>	99 1
			los
		<u></u>	미
	Short	Z	<u>a</u>
	ort.	_ 5	
		d	
		-	
	Ва	335 - 31 V	1171
	Sic		
	Basic Long		
	UQ		
	5		
	ginc		
	īvid		
	ziler		
	ed C		
	NS/I		
	Ę		
	Long individualized CNS/FLQ/XDR		

Patien
t Sticker

Patient Name		Date of Birth (dd/mm/yyyy)	/mm/yyyy)
Patient Identity Number		Age (years)	
Gender	Allergies		
Patient Address			
Patient Contact Number			
Patient Hospital Number			
Treatment Supporter Contact Number	Number		
Patient TB Numbers (Previous and Current)	and Current) 1.	2.	3.
Treatment Start Date (current episode)	episode)		
Delaminid (DL) Approval Number)er		
Delaminid (DLM)Treatment	Start	Stop	
Bedaquiline start date	Beda	Bedaquiline end date	
Bedaquiline extension date	DLM extension	ension date	

Start / Change Date	Write the start date of th	ne initial regimen and enter date	Write the start date of the initial regimen and enter date when the regimen changed or meds stopped
Patient Sticker	lf an elec	If an electronic sticker is available with patient det	atient details this can be used
Patient Name	As it appears in the i.D.	Age Used to verify dose	Gender Indicate male (M) or female(F)
Date of Birth	Use format date / month / year	year Identity Number	Use the green bar-coded south African I.D. number. If the patient is not a South African Citizen indicate in the relevant field
Patient Address	Try and identify landmarks if possible to trace patients if lost to follow up.	possible Patient Contact ow up. Number	Used to contact patient. If possible call patient to verify number when registering.
Patient Hospital Number	Hospital specific number	Treatment Supporter Contact Number	Used to try and trace patient if lost to follow up.
Patient TB Numbers (Previous)	Unique EDR TB number given to patient if there was a previous episode.	en to Patient TB Numbers ious (Current)	New EDR TB number given to patient for current episode
Delaminid (DL) Approval Number	DLM is restricted to certain pat DL number issued. This numbe from Province).	DLM is restricted to certain patients. Approval to use DLM will be given DL number issued. This number must be written on the prescription by from Province).	be given by the centralized hospital and a unique iption by the doctor (refer to latest communication
Delaminid Treatment	DLM is indicated for 6 months.	DLM is indicated for 6 months. Duration may be extended by the Clinica	the Clinical Committee if necessary. Indicate start
start / stop date	and expected stop date for the first course of DLM.	e first course of DLM.`	
	Duration more than 6 months to be	to be	Duration more than 6 months to be
BDQ extension	approved by the clinical committee Indicate start date of extension.	nittee. Delaminid extension	tension approved by the clinical committee. Indicate start date of extension.
Risk Factors and Allergies	Indicate if patient has any aller	rgies or risk factors such as co-n	Indicate if patient has any allergies or risk factors such as co-morbidities or renal complications

PREVIOUS EPISODES, DRUG EXPOSURE AND TREATMENT OUTCOMES

TYPE(ti	DR TB
ck) Previously (PT2)	Prev
ously Treated wit	Previously treated
h sec	υ. ≦.
ond line dr	th 1 st line drugs
ugs	(PT1)
ART ST/	HIV Sta

ART START DATE:	HIV Status Neg
REGII	Pos
REGIMEN:	om Arti

Medicine (tick if previous exposure)	if previous re)	START DATE	STOP DATE	REASON FOR STOP	DURATION: OF EXPOSURE
Bedaquiline	0				
Linezolid			TENNAMENT TO THE PROPERTY OF T		
Clofazimine	D	And the section of th			
Levofloxacin		TO DESCRIPTION OF THE PROPERTY			
Moxifloxacin			and the state of t		
Isoniazid		and the second s	7.00		
Ethambutol	0	CONTRACT PRODUCTION	The state of the s		
Pyrazinamide	0		Water to the state of the state		
Delaminid	ם				
Ethionamide	0		and the second of the second o		
PAS		a de la companya de l			
Terizidone			The state of the s		
lmipenem			a depth dept	10 mg/m/2/2 4 f 2	
Amoxicillin / clavulanic	/ulanic 🗆 📗		The state of the s		
Kanamycin			Addition to the second of the		
Amikacin					

	Curren	it episode (Tick dia	Current episode (Tick diagnosis based on lab results)	b results)		
Mono-resistant	MDR T	MDR TB Not Confirmed		Pre-XDR TB ((FQ)	
Poly-resistant	MDR 1	MDR TB Confirmed		Pre-XDR TB (I	(Injectable)	
Rifampicin RR	XDR T	XDR TB Not Confirmed		XDR TB Confi	nfirmed	
Mutations	A HNI		Kat G □	Both		
						And the state of t

Amikacin 15mg-20/kg	Amoxicillin — Clavulanic acid	Meropenam 20-40mg/kg 8 hourly (or Imipenem 12 hourly)	PAS (200-300mg/kg)	Delamanid – BD.	Ethionamide 15-20mg/kg	Pyrazinamide20-30mg/kg	Ethambutol 15-25mg/kg	Isoniazid (High) 10-15mg/kg	Isoniazid (STD), 4-6mg/kg	Clofazimine (2-5mg/kg)	Terizidone 15-20mg/kg	Bedaquiline	Linezolid (10mg/kg)	Moxifloxacin (10-15mg/kg) (high dose—in brackets)	Levofloxacin (15-20mg/kg)	Wledicine	Dosa
625mg		750mg-1g		100mg	500mg	750-1000mg	800mg	450mg	200mg	100mg	500mg		600mg	400mg	750mg	30-35kg_	ges advocated in DR 1
750mg	125 mg clavulanic acid	18	88	100mg	500mg	1500mg	800mg	450mg	300mg	100mg	500-750mg	400mg daily for 2 weeks — thereafter	600mg	400mg (600mg)	750mg	36-45kg	Dosages advocated in DR TB — in adults and children > 6 (November 2019 update)
750-1g	d - 30 minutes before carbepenam given	18	8g	100mg	750mg	1500mg	1200mg	600mg	300mg	100mg	750mg		600mg	400mg (600mg)	1000mg	46-55kg	ren > 6 (November 20
100	carbepenam given	16	8g	100mg	750mg	1500mg	1200mg	600mg	300mg	100mg	750mg	200 mg 3 times a week	600mg	400mg (800mg)	1000mg	56kg to 70kg	19 update)
ј-3. Оо		18	Se	100mg	750mg	2000mg	1200mg	600mg	300mg	100mg	750mg		600mg	400mg (800mg)	1000mg	>70kg	

^{**} Doses may differ in other Provinces. Please consult the latest guidelines. Paediatric doses are not included.

Pat
ient i
Vame
עו

TB No. _

Initial ARV prescription

		Fluconazole	Cotrimoxazole	Atazanavir/r	Dolutegravir	Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	mg	Medicine	Section B: ART Prescription	CD4	Review Date	Date
	Acute	Daily po	Daily po	Daily po	Daily po	BD po	Daily po	Daily po	Daily po	Daily po	Daily po		Freq. Duration	otion	WIRALLOAD	Weight	Ward
	Acute Medication											dispenser	Oty. Signature Date			Rresenper	
											4	Uare Time	1 2 3 4	Section B: Administrat		en signature	
	Con						And the second s						5 6 7 8 9 10	istration Record For In Patients			
	Comments												11 12 13 14	nts		Qualifications	

DAY 1-14 ARV PRESCRIPTION

		Fluconazole	Cotrimoxazole	Dolutegravir (DTG)	Lopinovir/ritonavir	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	Medicine	Section B : ART Prescription	CD4	Date : Review:Date
					***						Dose mg	réscription		
1000		Daily po	Daily po	Daily po	BD po	Dally po	Daily po	Daily po	Daily po	Daily po	Freq.		VI	W
100000000000000000000000000000000000000	Addition	14 days	14 days	14 days 14 days	14 days	14 days	14 days	14 days	14 days	14 days	Duration		VIRAL LOAD	Ward Weight
i i i i i i i i i i i i i i i i i i i	Additional Acute Medication										Qty, d			
	edication										Signature of Da		·	P _r
											Date Date Time	Sect		Prescriber
											Y 2	Section B: Adminis		
4												inistration		Signature
											6 7 8	tration Record For In Patients		
	Comn										9 10 11	In Patients		Qualifications
	Comments										11 12 13			tions.
											3 14			

DAY 15-28 ARV PRESCRIPTION (FOR INPATIENTS AND OUTPATIENTS)

	Review Date	Date
	Weight	Ward
	Prescriber	
	Signature	
A CANADA	Qualifications	

The second secon					.,		
		Cotrimoxazole Fluconazole	Dolutegravir (DTG) Atazanavir/r	AZT/3TC Lopinovir/ritonavir	TDF/FTC ABC/3TC	TDF/STC/DTG TDF/FTC/EFV	Section A.: AKII Prescription Medicine Medicine mg
						- Control	Scription Dose mg
a service serv		Daily po	Daily po Daily po	Daily po BD po	Daily po Daily po	Daily po Daily po	Freq
	Addition	14 days 14 days	14 days 14 days	14 days 14 days	14 days 14 days	14 days 14 days	Duration
	Additional Acute Medication	444					Oty. Sign
	ledication						Signature of dispenser Date
	ī					4	
E.							Section 8 Administration Day 15 16 17 1 1 Date Time
							17 18 19
							Ord Fo
	Comments						24 25 26 27 28
							26 27
							28

atient Name_
TB No

MONTHLY INPATIENT ARV PRESCRIPTION	Y INP	ATIE	A TN	8	PRES	SCRIP	PTIC	S																			
)ate			Wai	ď	Ward			ŀ					ĺ														Í
łeview Date			Weight	ght					-10	Prescriber	ber				Signature	ture					Qualifications	ific:	tion	್ರ			
<u>1</u> 04			VIR/	VIRAL LOAD	Φ.				, and the state of															ľ			
ection A.: ART Prescription	scription				Section B: Administration Record For In Patients	n B	Admir	istra	ion R	ecorio	For	n Pat	ients				I										
bose					Day	1 2	w 4	۷.	6 7	8	9 10	11	13	13 14	ĸ	16	17	18 19	20	22	22	23	24	25	26	27	28
Wedicine	Freq DUR	DUR		95	Date V								_	_]	_	-		-	\dashv	1					
TDF/3TC/DTG	Daily po	1/12	ро														_		\dashv	\dashv		\top	\exists			_	-
TDF/FTC/EFV	Daily po	1/12	g		⋖	-								-					\dashv	\dashv		\dashv					
TDF /FTC	Daily po	1/12	рo											-			-	+	+	1	+	\dagger		_			
ABC/3TC	Daily po	1/12	po															-					1				
AZT/ 3TC	Daily po	1/12	po														-	-	\dashv		+	\dashv	\dashv				
Lopinovir/r	BD po	1/12	po		_						-								\dashv	1	\dashv	\dashv					
Dolutegravir	Daily po	1/12	ро															\dashv			\dashv	\dashv	1		\prod	1	
Atazanavir/r	Daily po	1/12	Po																		1	1	\dashv			_	
Cotrimoxazole	Daily po	1/12	Ро													_	-	-				\dashv					
Fluconazole	Daily po	1/12	po																		-	1	\dashv				
																		_				-					
··· continuos																											
				K SHIPMER'S														-	\dashv		1					_	
	1			Ä.	Additional Acute Medication	al Acut	e Med	cation							•						: Comments	ã l	nen En	ਲ			
																									2000		
										-																	
			_																								
			-																								i
7,000																											
Dispensed hv:	**					;																					
1	:					,																					

Patient Name
TB 7
ō

MONTHLY INPATIENT ARV PRESCRIPTION

Dispen										- STANGE	 Fluconazole	Cotrimoxazole	Atazanavir/r	Dolutegravir	Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	Injection.	Martigina	Section A: ART Prescription	CD4.	Review Date	Date
Dispensed by:			1000000			***************************************					Daily po	Daily po	Daily po	Daily po	BD po	Daily po	Daily po	Daily po	Daily po	Daily po	Mg	120	T Prescription			
					:						1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	NEW	0				
		-	ļ	-		-		_			8	Ро	Po	ро	B	po	B	od	ро	po				VIR	We	Ward
			į					٥	L												Ci)		*	VIRALLOAD	Weight	ď
,								Additional Acute Medication											₩.		Date Time	Day 1	Section	AD		
Date:								Acute Med														2 3	Section B. Administration Record For In Patients			
								ication														# %	nistratio			
																						7 8	n Record		1000	Presoriher
																						9 10	For In		20))
																						11 12	Patient			
																						13 14	S		0.6	c.
							-															15 16			Sharule	3
																						17 18				
***************************************																						19 20				
																						21 22			Quali)
	-							Comments											1			29 24			Qualifications	
								ts										-				25 26	Section 1		V.	
																						y6 27				TO SERVICE SER
										 							EX					28		war sect		

Patient Name
\lame
າe
TB No

MONTHLY INPATIENT ARV PRESCRIPTION

×42			100											-						
Review Date			Weight					Prescriber	riber			Signa	ature			Qua	Qualifications	suc		
Section A : ART Prescription	otion	7		Section	on B: A	Section B: Administration Record For In Patients	stratio	າ Reco	rd For	n Pati	ants									
7 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -				-	1 2	\$ 4	9 5	7 8	9 10	ıı	12 13	14 15	16 17	18	19 20	21 22	23	24 25	26 27	28
Wedicine. We	Freq. D	DUR	Oty .	Date																-
TDF/3TC/DTG D	Daily po 1/	1/12 p	po																<u> </u>	_
		1/12	po	*																-
	Daily po 1/	1/12 F	po																	-
	Daily po 1,	1/12 6	В												-			ļ		-
AZT/3TC D	Daily po 1,	1/12 F	ро																	-
,	8D po 1,	1/12 r	po																	-
•	Daily po 1,	1/12 6	po									<u> </u>								-
	Daily po 1,	1/12 F	Po					_							ļ <u>.</u>					ļ ·
(D		1/12 1	Ро																	-
	Daily po 1,	1/12 1	В									_			-		-			4

Adam													•							<u></u>
																				<u> </u>
															-			<u> </u>		!
				Additional Acute Medication	nal Acut	e Medic	ation										Comments	ents		
AND THE PROPERTY OF THE PROPER																				
LIVANIA	***																			
t. Investable																				
														_						

Dispensed by: _

Date: _

Patient Name	
TB No.	

MONTHLY INPATIENT ARV PRESCRIPTION

		Т	[1	Ĭ		66			T	T		******	,												1/2
							***					Fluc	Cotrimoxazole	Ataz	Dolu	Lop	AZ	ΑB	Ŧ	TDF/	TDF/	Š		Section A: ART Prescription	Review Date	Date
Dis												Fluconazole	noxa	Atazanavir/r	Dolutegravir	Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	Medicine		on A	w Da	
pen						1						ole	zole	r/r	vir	'n	C	Э.	C	ΞFV	OTG			AR	ਰੰ	
Dispensed by:																						Mg	Dose	Pre		
۰ ۲:		·					ý. W					De	8	D	D	<u> </u>	D	Da	Da	Da	Da			scrip		
			-									Daily po	Daily po	Daily po	Daily po	8D po	Daily po	Daily po	Daily po	Daily po	Daily po	rrea.		tion		
												1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	1/12	DUK	300mm25a10			
				*						<u> </u>		g	Po	Po	po po	po	po	? po	? po	2 po	po			1		
						ļ			-	_									_			Č	hr .		Weight	pienn
							A								-		400-1					G.	Ť		큐	
							Additional Acute Medication													*		Date Time	Day	Section B: Administration Record For In Patients		
							nal A																۲	ion		
Date:							cute																2 3	3: Ad		
1							Vledio	-												'			4	min Din		
				Ì			ation																S	stra		
									_		ļ	ļ 											6	ion		9868
	_			 <u> </u>																			7 8	Reco	Prescriber	
										<u> </u>	_												9	rd F	cribe	
																							10	or In		
																							11	Pati		
									<u> </u>														12 13	ents		
								-															.3 14			
																							1.5		Sign	
				•	:																		16		ature	
																							17	2	,	
	-																						1.8			١
																							19 :			
																							20 21			
									_									_					1 22		Qua	
							Comments		<u></u>	-								-					2 23		Qualifications	
							nen																24		ation	
																							25		S	
																							26		- Presson	
							7			ļ								_					27			
								Ĭ								- 1							28			ļ

atient Name
TB No.

Dispensed by: ______ Date: _____

MONTHLY INPATIENT ARV PRESCRIPTION

Disp			 						Fluconazole	Cotrimoxazole	Atazanavir/r	Dolutegravir		Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	antarta State	Wediging	Section A : ART Prescription	Review Date	Date
Dispensed by:									ē	Ole I	<u>'</u> 'r	/ir			'		. ,	7	TG	Mg		ART Pres	e e	
¥: 									Daily po	Daily po	Daily po	Daily po		<u></u> B	Daily po	Daily po	Daily po	Daily po	Daily po	11541	September 1995	cription		
									1/12	1/12	1/12	1/12	<u>}</u>	1/12	1/12	1/12	1/12	1/12	1/12	007	2 6			
			-	-			ŀ		g	Ро	Ро	ро	7	3	po	po	po	ро	po				We	Wa
																				Ţ)		ight	Ward
 					Additional Acute Medication													4		Date Time	Day	Section B: Administration Record For In Patients		
D					nál Acı			<u> </u>												<u> </u>	1 2	on B		
Date:					ite M	-							-						***********		3	Adn		
					edicat		ļ														4	ninis		
					ion	H	_							}							5 6	ratio		
																					7	iń Re		0
					1		L.	ļ	_												to	cord	200	Deposedhen
						ļ		<u> </u>			_										9 10	For	Č	Fon
						\vdash		<u> </u>													11	ln Pa	18; "ESSAS	
																		\dashv			12	itien		
'																					13	Ġ		
																					14		O OF	Ω.
																	_				15		51101	9
							_	ļ													16		alule	3
								ļ									\dashv				17			
					1																18 19			
									 	-	1		-		\dashv						9 20			
	-																	-			21.		le de	
					Cc												1				22		Qualitications	
					Comments											1					23		ll Ca	*
					nen																24		ilan	<u> </u>
	-				S																25		Y	222
																	_	_			26			
		İ							_	_	\perp					_					27			
								and held singuishess						··· anderson							섫		i mana mana	

	$\boldsymbol{\tau}$
	σ)
	=
	_
	_
	æ
	~
	_
	_
	വ
	_
	=
	ന
t	• • •

IB No.

OUTPATIENT ARV PRESCRIPTION

,	944			Qualifications	Signature of Dispenser	Name of Prescriber		Fluconazole	Cotrimoxazole	Atazanavir/r	Dolutegravir	Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	Medicine Dose				(Craix	
	- Win				er			Daily po	Daily po	Daily po	Daily po	BD po	Daily po	Daily po	Daily po		18	Freq	ì				
			A					28	28	28	28	28	28	28	28	28 .	(Days) 28	Dur	4				
	1993		Additional Acute Medication															QTY Sign = Date	Viral load	CD4	Weight	Date	Month
			Medication														ĝ	OTY VIEW Date	Viral load	CD4	Weight	Date	Month
																	CH SIEN Date		Viral load	CD4	Weight	Date	Month
		William Control of the Control of th															yir bign Date		Viral load	CD4	Weight	Date	Month
The state of the s			(Comments														QTY Sign Date		Viral load	CD4	Weight	Date	Month
	·		Pents													- W	©™ Sign ← Date		Viral load	CD4	Weight	Date	Month

Pat
tient
2 a n
ne

급	
2	
•	
1	

OUTPATIENT ARV PRESCRIPTION

	Chamications	Oualifications	Signature of Dispenser	Name of Prescriber		Fluconazole	Cotrimoxazole	Atazanavir/r	Dolutegravir	Lopinovir/r	AZT/3TC	ABC/3TC	TDF /FTC	TDF/FTC/EFV	TDF/3TC/DTG	Medicine Dose				3.2	
			er			Daily po	Daily po	Daily po	Daily po	BD po	Daily po	Daily po	Daily po	Daily po	Daily po	iFreq.					
						28	28	28	28	28	28	28	28	28	28	Dyrc Days)		1			
	Additional Acute Medication							###Www.nidor.com								QTY° Sign Date	Viral load	CD4	Weight	Date	Month
	Medication														Of the state of th	OTY Sign Date	Viral load	CD4	Weight	Date	Month
														and the state of t		QTY Sign Date	Viral load	CD4	Weight	Date	Month
																OTY Sgr Date	Viral load	CD4	Weight	Date	Month
Loimin Roma																QTY Sign Date.	Viral load	CD4	Weight	Date	Month
Comments:																OTY Sign Date	Viral load	CD4	Weight	Date	Month

	٠.
	تو
-	~
	D
	\neg
	\supset
	ct
	Name of
	_
	_
	ລັ
	3
	3
,	
1	3
]	3

젊	
2	
•	
į	

OUTPATIENT ARV PRESCRIPTION

Extreme limitation in activity, significant assistance required; significant medical intervention/ therapy required,	Marked limitation in activity, Some assistance usually required; medical intervention/ therapy required, hospitalizations	Mild to moderate limitation in activity some assistance may be needed; no or minimal medical intervention/ Therapy required.	Mild to mode some assists or minimal	mild nours); no ention/ ired	Iransient or mild discomfort (<48 hours); no medical intervention/
Grade 4 Life threatening - Report	Grade 3 Severe - Report	Grade 2 Moderate	Grac	Aild.	Grade 1 Mild
Assess for surgical intervention if indica	Stop offending drugs. Wait for resolution. Assess for surgical intervention if indicated	Ethionamide	EFV.		чупаесоmastia
pecause of life-threatening rash.*#	 Thioacetazone is contraindicated in HIV because of life-threatening rash.*# 	<u> </u>)
	 causes Stevens-Johnson syndrome Consider SMX/TMP as a potential cause 	1	ABC, NVP, EFV, d4T and other	ABC,	Skin rash
in life-threatening anaphylaxis) or an a	• Do not re-challenge with ABC (can result in life-threatening anaphylaxis) or an agent that	Any drug can cause			
ions need to be dose adjusted for renal	 Many ARV and anti-tuberculosis medications need to be dose adjusted for renainsufficiency 	7.70			
itoring every 1-3 weeks is recommende	 Frequent creatinine and electrolyte monitoring every 1-3 weeks is recommended 	E/ Lfx to 3 x week)	reduced it severe		
nd.uncontrolled diabetics will have an osside and Cm	 Even without TDF, HIV-infected patient and uncontrolled diabetics will have an increased risk of renal toxicity secondary to aminoglycoside and Cm 	-	may have to be	ma C	Renal toxicity
aminoglycosides or Cm	 Use TDF with caution in patient receiving aminoglycosides or Cm 				
7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	 TDF may cause acute renal failure 				
and replace. If drug is critical (e.g. LZD i	 Suspend agent responsible permanently and replace. If drug is critical (e.g. LZD in an XDR could rechallenge at half dose - once settles 	E, Lzd, Eto (rare)	ddl		Optic neuritis
neuropathy develops, replace the ARV agent Pregabalin may relieve pain	 if Cs or Lzd must be used and peripheral neuropathy develops, replace with a less neurotoxic agent. Gabapentin / Pregabalin may relieve pain 	Eto, E			neuropathy
Cs or Lzd; may increase peripheral neur	 Avoid d4T, ddl, ddC in combination with Cs or Lzd; may increase peripheral neuropathy. 	Lzd, Cs, Trd, H,	d4T ddl ddC	<u></u>	Peripheral
t permanently and do not use any of the in the future.	 If an agent causes pancreatitis suspend it permanently and do not use any of the pancreatitis producing ant-HIV medications in the future. 				and the second s
itial cause	• Consider gallstones or alcohol as a potential	Lzd/ BDQ - (Rare)	d4T,ddl,ddC	Ω.	Pancreatitis
	Avoid concurrent use.				
osis and/or hepatitis if there is persister	 Check for medication-induced lactic acidosis and/or hepatitis if there is persistent vomiting and abnormal pain. / rehydrate 	PAS, H, E, Z and others	most others		vomiting
ecially Eto + PAS	• These are common adverse effects. Especial	BDQ, DLM, Eto,	RTV, d4T, NVP, and		Nausea and

BIDDER'S DISCLOSURE

4	DUDDA	OSE OF	THE	EODM
	PURP	ノント ひと		FURIN

Any person (natural or juristic) may make an offer or offers in terms of this invitation to bid. In line with the principles of transparency, accountability, impartiality, and ethics as enshrined in the Constitution of the Republic of South Africa and further expressed in various pieces of legislation, it is required for the bidder to make this declaration in respect of the details required hereunder.

Where a person/s are listed in the Register for Tender Defaulters and / or the List of Restricted Suppliers, that person will automatically be disqualified from the bid process.

2. BIDDER'S DECLARATION

- 2.1. Is the bidder, or any of its directors / trustees / shareholders / members / partners or any person having a controlling interest¹ in the enterprise, employed by the state?

 YES/NO
- 2.1.1 If so, furnish particulars of the names, individual identity numbers, and, if applicable, state employee numbers of sole proprietor/directors / trustees / shareholders / members/ partners or any person having a controlling interest in the enterprise, in table below.

Full Name	Identity Number	Name of State Institution

- 2.2. Do you, or any person connected with the bidder, have a relationship with any person who is employed by the procuring institution?

 YES/NO
- 2.2.1. If so, furnish particulars:
- 2.3. Does the bidder or any of its directors / trustees / shareholders / members / partners or any person having a controlling interest in the enterprise have any interest in any other related enterprise whether or not they are bidding for this contract? YES/NO
- 2.3.1. If so, furnish particulars:

3. DECLARATION

- I, the undersigned (name) in submitting the accompanying bid, do hereby make the following statements that I certify to be true and complete in every respect:
- 3.1. I have read and I understand the contents of this disclosure;
- 3.2. I understand that the accompanying bid will be disqualified if this disclosure is found not to be true and complete in every respect;
- 3.3. The bidder has arrived at the accompanying bid independently from, and without consultation, communication, agreement or arrangement with any competitor. However, communication between partners in a joint venture or consortium² will not be construed as collusive bidding.
- 3.4. In addition, there have been no consultations, communications, agreements or arrangements with any competitor regarding the quality, quantity, specifications, prices, including methods, factors or formulas used to calculate prices, market allocation, the intention or decision to submit or not to submit the bid, bidding with the intention not to win the bid and conditions or delivery particulars of the products or services to which this bid invitation relates.
- 3.5. The terms of the accompanying bid have not been, and will not be, disclosed by the bidder, directly or indirectly, to any competitor, prior to the date and time of the official bid opening or of the awarding of the contract.
- 3.6. There have been no consultations, communications, agreements or arrangements made by the bidder with any official of the procuring institution in relation to this procurement process prior to and during the bidding process except to provide clarification on the bid submitted where so required by the institution; and the bidder was not involved in the drafting of the specifications or terms of reference for this bid.
- 3.7. I am aware that, in addition and without prejudice to any other remedy provided to combat any restrictive practices related to bids and contracts, bids that are suspicious will be reported to the Competition Commission for investigation and possible imposition of administrative penalties in terms of section 59 of the Competition Act No 89 of 1998 and or may be reported to the National Prosecuting Authority (NPA) for criminal investigation and or may be restricted from conducting business with the public sector for a period not exceeding ten (10) years in terms of the Prevention and Combating of Corrupt Activities Act No 12 of 2004 or any other applicable legislation.

I CERTIFY THAT THE INFORMATION FURNISHED IN PARAGRAPHS 1, 2 and 3 ABOVE IS CORRECT.

I ACCEPT THAT THE STATE MAY REJECT THE BID OR ACT AGAINST ME IN TERMS OF PARAGRAPH 6 OF PFMA SCM INSTRUCTION 03 OF 2021/22 ON PREVENTING AND COMBATING ABUSE IN THE SUPPLY CHAIN MANAGEMENT SYSTEM SHOULD THIS DECLARATION PROVE TO BE FALSE.

Name of Bidder	Signature	Position	Date
Name of Bloder	Signature	Position	Date

¹ the power, by one person or a group of persons holding the majority of the equity of an enterprise, alternatively, the person/s having the deciding vote or power to influence or to direct the course and decisions of the enterprise.

² Joint venture or Consortium means an association of persons for the purpose of combining their expertise, property, capital, efforts, skill and knowledge in an activity for the execution of a contract.

SPECIAL CONTRACT CONDITIONS OF QUOTATIONS

1. AMENDMENT OF CONTRACT

1.1. Any amendment to or renunciation of the provisions of the contract shall at all times be done in writing and shall be signed by both parties.

2. CHANGE OF ADDRESS

2.1. Bidders must advise the Department of Health (institution where the offer was submitted) should their address (domicilium citandi et executandi) details change from the time of bidding to the expiry of the contract.

3. GENERAL CONDITIONS ATTACHED TO THIS QUOTATION

3.1. The Department is under no obligation to accept the lowest or any quote.

- 3.2. The Department reserves the right to communicate in writing with vendors in cases where information is incomplete or where there are obscurities regarding technical aspects of the offer, to obtain confirmation of prices or preference claims in cases where it is evident that a typing, written, transfer or unit error has been made, to investigate the vendor's standing and ability to complete the supply/service satisfactorily.
- 3.3. ALL DECÍSIONS TAKEN BY THE DEPARTMENT ARE FINAL, INCLUDING THE AWARD OR CANCELLATION OF THIS QUOTATION.

3.4. The price quoted must include VAT (if VAT vendor).

3.5. Should a bidder become a VAT vendor after award or during the implementation of a contract, they may not request the VAT percentage from the Department as the service provider made an offer during the period they were not registered as a VAT vendor. The Department is only liable for any VAT from registered VAT vendors as originally stated on the quotation document.

3.6. The bidder must ensure the correctness & validity of the quotation:

(i) that the price(s), rate(s) & preference quoted cover all for the work/item (s) & accept that any mistakes regarding the price (s) & calculations will be at the bidder's risk

(ii) it is the responsibility of the bidder to confirm receipt of their quotation and to keep proof thereof.

- 3.7. The bidder must accept full responsibility for the proper execution & fulfilment of all obligations conditions devolving on under this agreement, as the Principal (s) liable for the due fulfilment of this contract.
- 3.8. This quotation will be evaluated based on the 80/20 points system, specification, correctness of information and/or functionality criteria.

 All required documentation must be completed in full and submitted.

3.9. Offers must comply strictly with the specification.

3.10. Only offers that meet or are greater than the specification will be considered.

3.11. Late offers will not be considered.

3.12. Expired product/s will not be accepted. All products supplied must be valid for a minimum period of six months.

3.13. Used/ second-hand products will not be accepted.

3.14. A bidder not registered on the Central Suppliers Database or whose verification has failed will not be considered.

3.15. All delivery costs must be included in the quoted price for delivery at the prescribed destination.

- 3.16. Only firm prices will be accepted. Such prices must remain firm for the contract period. Non-firm prices (including rates of exchange variations) will not be considered.
- 3.17. In cases where different delivery points influence the pricing, a separate pricing schedule must be submitted for each delivery point.
- 3.18. In the event of a bidder having multiple quotes, only the cheapest according to specification will be considered.

3.19. Verification will be conducted to identify if bidders have multiple companies and are cover-quoting for this bid.

3.20. In such instances, the Department reserves the right to immediately disqualify such bidders as cover-quoting is an offence that represents both corruption and acquisition fraud.

4. SPECIAL INSTRUCTIONS AND NOTICES TO BIDDERS REGARDING THE COMPLETION OF THIS QUOTATION.

- 4.1. Unless inconsistent with or expressly indicated otherwise by the context, the singular shall include the plural and vice versa and with words importing the masculine gender shall include the feminine and the neuter.
- 4.2. Under no circumstances whatsoever may the quotation/bid forms be retyped or redrafted. Photocopies of the original bid documentation may be used, but an original signature must appear on such photocopies.

4.3. The bidder is advised to check the number of pages and to satisfy himself that none are missing or duplicated.

- 4.4. Quotations submitted must be complete in all respects. However, where it is identified that information in a bidder's response, which does not affect the preference points or price, is incomplete in any respect, the said supplier meets all specification requirements and scores the highest points in terms of preference points and price, the Department reserves the right to request the bidder to complete/submit such information.
- 4.5. Any alteration made by the bidder must be initialled; failure to do so may render the response invalid.

4.6. Use of correcting fluid is prohibited and may render the response invalid.

4.7. Quotations will be opened in public as soon as practicable after the closing time of quotation.

4.8. Where practical, prices are made public at the time of opening quotations.

4.9. If it is desired to make more than one offer against any individual item, such offers should be given on a photocopy of the page in question. Clear indication thereof must be stated on the schedules attached.

4.10. The Department is under no obligation to pay suppliers in part for work done if the supplier can no longer for fulfil their obligation.

5. SPECIAL INSTRUCTIONS REGARDING HAND DELIVERED QUOTATIONS

- 5.1. Quotation shall be lodged at the address indicated not later than the closing time specified for their receipt, and in accordance with the directives in the quotation documents.
- 5.2. Each quotation shall be addressed in accordance with the directives in the quotation documents and shall be lodged in a separate sealed envelope, with the name and address of the bidder, the quotation number and closing date indicated on the envelope. The envelope shall not contain documents relating to any quotation other than that shown on the envelope. If this provision is not complied with, such quotations/bids may be rejected as being invalid.
- 5.3. All quotations received in sealed envelopes with the relevant quotation numbers on the envelopes are kept unopened in safe custody until the closing time of the quotation/bids. Where, however, a quotation is received open, it shall be sealed. If it is received without a quotation/bid number on the envelope, it shall be opened, the quotation number ascertained, the envelope sealed and the quotation number written on the envelope.
- 5.4. A specific box is provided for the receipt of quotations, and no quotation found in any other box or elsewhere subsequent to the closing date and time of quotation will be considered.
- 5.5. No quotation/bid sent through the post will be considered if it is received after the closing date and time stipulated in the quotation documentation, and proof of posting will not be accepted as proof of delivery.
- 5.6. Quotation documents must not be included in packages containing samples. Such quotations may be rejected as being invalid.

6. SAMPLES

- 6.1. In the case of the quote document stipulating that samples are required, the supplier will be informed in due course when samples should be provided to the institution. (This decreases the time of safety and storage risk that may be incurred by the respective institution). The bidders sample will be retained if such bidder wins the contract.
- (i) If a company/s who has not won the quote requires their samples, they must advise the institution in writing of such.
- (ii) If samples are not collected within three months of close of quote the institution reserves the right to dispose of them at their discretion.
- 6.2. Samples must be made available when requested in writing or if stipulated on the document.
- (i) If a Bidder fails to provide a sample of their product on offer for scrutiny against the set specification when requested, their offer will be rejected. All testing will be for the account of the bidder.

7. COMPULSORY SITE INSPECTION / BRIEFING SESSION

- 7.1. Bidders who fail to attend the compulsory meeting will be disqualified from the evaluation process.
- (i) The institution has determined that a compulsory site meeting take place.
- (ii) Date 01 / 11 / 2022 Time 11 : 00 Place CATHERINE BOOTH HOSPITAL DINNING ROOM

Institution Stamp:	Institution Site Inspection / briefing session Official
<i>7</i> 4	Full Name:
	Signature:
	Date:

8. STATEMENT OF SUPPLIES AND SERVICES

8.1. The contractor shall, when requested to do so, furnish particulars of supplies delivered or services executed. If he/she fails to do so, the Department may, without prejudice to any other rights which it may have, institute inquiries at the expense of the contractor to obtain the required particulars.

9. SUBMISSION AND COMPLETION OF SBD 6.1

9.1. Should a bidder wish to qualify for preference points they must complete a SBD 6.1 document. Failure by a bidder to provide all relevant information required, will result in such a bidder not being considered for preference point's allocation. The preferences applicable on the closing date will be utilized. Any changes after the closing date will not be considered for that particular quote.

10. TAX COMPLIANCE REQUIREMENTS

- 10.1. In the event that the tax compliance status has failed on CSD, it is the suppliers' responsibility to provide a SARS pin in order for the institution to validate the tax compliance status of the supplier.
- 10.2. In the event that the institution cannot validate the suppliers' tax clearance on SARS as well as the Central Suppliers Database, the quote will not be considered and passed over as non-compliant according to National Treasury Instruction Note 4 (a) 2016/17.

TAX INVOICE

- 10.3. A tax invoice shall be in the currency of the Republic of South Africa and shall contain the following particulars:
- (i) the name, address and registration number of the supplier;
- (ii) the name and address of the recipient;
- (iii) an individual serialized number and the date upon which the tax invoice is issued;
- (iv) a description and quantity or volume of the goods or services supplied;
- (v) the official department order number issued to the supplier;
- (vi) the value of the supply, the amount of tax charged;
- (vii) the words tax invoice in a prominent place.

11. PATENT RIGHTS

The supplier shall indemnify the KZN Department of Health (hereafter known as the purchaser) against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

12. PENALTIES

- 12.1. If at any time during the contract period, the service provider is unable to perform in a timely manner, the service provider must notify the institution in writing/email of the cause of and the duration of the delay. Upon receipt of the notification, the institution should evaluate the circumstances and, if deemed necessary, the institution may extend the service provider's time for performance.
- 12.2. In the event of delayed performance that extends beyond the delivery period, the institution is entitled to purchase commodities of a similar quantity and quality as a substitution for the outstanding commodities, without terminating the contract, as well as return commodities delivered at a later stage at the service provider's expense.
- 12.3. Alternatively, the institution may elect to terminate the contract and procure the necessary commodities in order to complete the contract. In the event that the contract is terminated the institution may claim damages from the service provider in the form of a penalty. The service provider's performance should be captured on the service provider database in order to determine whether or not the service provider should be awarded any contracts in the future.
- 12.4. If the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance.

13. TERMINATION FOR DEFAULT

- 13.1. The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:
- (i) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract,
- (ii) if the supplier fails to perform any other obligation(s) under the contract; or
- (iii) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.
- 13.2. In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar goods, works or services.
- 13.3. Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.
- 14. THE DEPARTMENT RESERVES THE RIGHT TO PASS OVER ANY QUOTATION WHICH FAILS TO COMPLY WITH THE ABOVE.

PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2017

This preference form must form part of all quotes invited. It contains general information and serves as a claim form for preference points for Broad-Based Black Economic Empowerment (B-BBEE) Status Level of Contribution

NB: BEFORE COMPLETING THIS FORM, BIDDERS MUST STUDY THE GENERAL CONDITIONS, DEFINITIONS AND DIRECTIVES APPLICABLE IN RESPECT OF B-BBEE, AS PRESCRIBED IN THE PREFERENTIAL PROCUREMENT REGULATIONS, 2017.

1. GENERAL CONDITIONS

- 1.1 The following preference point systems are applicable to all quotes:
 - the 80/20 system for requirements with a Rand value of up to R50 000 000 (all applicable taxes included); and
- 1.2 The value of this quote is estimated to not exceed R50 000 000 (all applicable taxes included) and therefore the 80/20 preference point system shall be applicable.
- 1.3 Points for this quote shall be awarded for:
 - (a) Price; and
 - (b) B-BBEE Status Level of Contributor.
- 1.4 The maximum points for this quote is allocated as follows:

	POINTS
PRICE	80
B-BBEE STATUS LEVEL OF CONTRIBUTOR	20
Total points for Price and B-BBEE must not excee	d 100

- Failure on the part of a bidder to submit proof of B-BBEE Status level of contributor together with the quote, will be interpreted to mean that preference points for B-BBEE status level of contribution are not claimed.
- 1.6 The purchaser reserves the right to require of a bidder, either before a quote is adjudicated or at any time subsequently, to substantiate any claim in regard to preferences, in any manner required by the purchaser.

2. DEFINITIONS

- (a) "B-BBEE" means broad-based black economic empowerment as defined in section 1 of the Broad-Based Black Economic Empowerment Act;
- (b) "B-BBEE status level of contributor" means the B-BBEE status of an entity in terms of a code of good practice on black economic empowerment, issued in terms of section 9(1) of the Broad-Based Black Economic Empowerment Act;
- (c) "bid" means a written offer in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of goods or services, through price quotations, advertised competitive bidding processes or proposals;
- (d) "Broad-Based Black Economic Empowerment Act" means the Broad-Based Black Economic Empowerment Act, 2003 (Act No. 53 of 2003);
- (e) "EME" means an Exempted Micro Enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- (f) "functionality" means the ability of a tenderer to provide goods or services in accordance with specifications as set out in the tender documents.
- (g) "prices" includes all applicable taxes less all unconditional discounts;
- (h) "proof of B-BBEE status level of contributor" means:
 - B-BBEE Status level certificate issued by an authorized body or person;
 - A sworn affidavit as prescribed by the B-BBEE Codes of Good Practice;
 - Any other requirement prescribed in terms of the B-BBEE Act;
- (i) "QSE" means a qualifying small business enterprise in terms of a code of good practice on black economic empowerment issued in terms of section 9 (1) of the Broad-Based Black Economic Empowerment Act;
- (j) "rand value" means the total estimated value of a contract in Rand, calculated at the time of bid invitation, and includes all applicable taxes;

3. POINTS AWARDED FOR PRICE

THE 80/20 PREFERENCE POINT SYSTEMS 3.1

A maximum of 80 points is allocated for price on the following basis:

$$Ps = 80 \left(1 - \frac{Pt - P\min}{P\min} \right)$$
 Where

Ps

Points scored for price of bid under consideration

Pt

Price of bid under consideration

Pmin

price of lowest acceptable bid

POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR 4.

In terms of Regulation 6 (2) and 7 (2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for 4.1 attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (80/20 system)
1	20
2	18
3	14
4	12
5	8
6	6
7	4
8	2
Non-compliant contributor	0

5	RIN	DECL	ARATION

- Bidders who claim points in respect of B-BBEE Status Level of Contribution must complete the following: 5.1
- B-BBEE STATUS LEVEL OF CONTRIBUTOR CLAIMED IN TERMS OF PARAGRAPHS 1.4 AND 4.1 6.

<u> </u>	B _* BBEE Status Level of Contributor:	=	(maximum of 20 points

(Points claimed in respect of paragraph 7.1 must be in accordance with the table reflected in paragraph 4.1 and must be substantiated by relevant proof of B-BBEE status level of contributor.

7.	SUB-CONTRACTING	
	applicable box)	

(Tick

**			
YES		NO	

NO

- 7.1 Will any portion of the contract be sub-contracted?
- 7.1.1 If yes, indicate:
 - What percentage of the contract will be subcontracted.....%
 - The name of the sub-contractor.....
 - The B-BBEE status level of the sub-contractor.....

8. Whether the sub-contractor is an EME or QSE (Tick applicable box)

Specify, by ticking the appropriate box, if subcontracting with an enterprise in terms of Preferential Procurement Regulations, 2017:

Designated Group: An EME or QSE which is at last 51% owned by:	EME	QSE
Besignated Group. All Elife of Got Willow to de last of the officer of	1	√ ;
Black people		
Black people who are youth		
Black people who are women		
Black people with disabilities		
Black people living in rural or underdeveloped areas or townships		
Cooperative owned by black people		
Black people who are military veterans		
OR		
Any EME		
Any QSE		

9.	DECLARATION WITH REGARD TO COMPANY/FIRM			
9.1	Name of company/firm:			
9.2	VAT registration number:			
9.3	Company registration number:			
9.4 TYPE OF COMPANY/ FIRM [TICK APPLICABLE BOX]		LE BOX]		
	 □ Partnership/Joint Venture / Consortium □ One person business/sole propriety □ Close corporation □ Company □ (Pty) Limited 			
9.5	DESCRIBE PRINCIPAL BUSINESS ACTIVITIE	ES		
9.6				
J. .0	 □ Manufacturer □ Supplier □ Professional service provider □ Other service providers, e.g. transporter 			
9.7	Total number of years the company/firm has be	een in business:		
9.8				
	i) The information furnished is true and correct;			
	ii) The preference points claimed are in accordance with the General Conditions as indicated in paragraph 1 of this form;			
	iii) In the event of a contract being awarded as a result of points claimed as shown in paragraphs 1.4 and 6.1, the contractor material be required to furnish documentary proof to the satisfaction of the purchaser that the claims are correct;			
	iv) If the B-BBEE status level of contributor has been claimed or obtained on a fraudulent basis or any of the conditions contract have not been fulfilled, the purchaser may, in addition to any other remedy it may have —			
	(a) disqualify the person from the bidding	process;		
	(b) recover costs, losses or damages it ha	as incurred or suffered as a result of that person's conduct;		
	(c) cancel the contract and claim any da arrangements due to such cancellatio	mages which it has suffered as a result of having to make less favourable n;		
	who acted on a fraudulent basis, be re	ctor, its shareholders and directors, or only the shareholders and directors estricted by the National Treasury from obtaining business from any organ 0 years, after the audi alteram partem (hear the other side) rule has been		
	(e) forward the matter for criminal prosect	ution.		
	WITNESSES	SIGNATURE(S) OF BIDDERS(S)		
	1			
		DATE:		
	2	ADDRESS		